Development of selective casein kinase 1 delta/epsilon inhibitors for cancer

Varování

Publikace nespadá pod Lékařskou fakultu, ale pod Přírodovědeckou fakultu. Oficiální stránka publikace je na webu muni.cz.

Autoři	GREGOROVÁ Michaela JANOVSKÁ Pavlína NĚMEC Václav SCHOLASTEROVÁ Michaela VERNER Jan POPPOVÁ Lucie PAVLOVÁ Šárka PLEVOVÁ Karla POSPÍŠILOVÁ Šárka PARUCH Kamil BRYJA Vítězslav
Rok publikování	2018
Druh	Konferenční abstrakty
Fakulta / Pracoviště MU	Přírodovědecká fakulta
Citace
Popis	Casein kinase 1 (CK1) is a key component of both canonical and non-canonical Wnt pathways, which were shown to drive chronic lymphocytic leukemia (CLL) by several mechanisms (Wang et al., 2014, Kaucka et al., 2013). Also other types of cancer, such as breast, prostate cancer or others were previously shown to depend on Wnt/CK1 activity and the pathway inhibition was suggested as a potential form of therapy. In recent study, we showed that CK1 inhibition can block processes involved in CLL progression in vitro as well as in vivo in the Eµ-TCL1 mouse model of CLL (Janovska et al., 2018). Importantly, CK1 inhibition showed synergistic effects with ibrutinib treatment in blocking chemotaxis of CLL cells, a process important for CLL pathogenesis and showed to be beneficial also in vivo.
Související projekty:	Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit V